Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17771171 | 0.86 | MEN1 (0.39) | MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL21503860 | 0.84 | MEN1 (0.38) | MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL22000502 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL13661777 | 0.77 | KCNA5 (0.31) | MEN1ALDH1A1HTTKMT2AKCNA5 | |
| SCHEMBL805360 | 0.77 | ACACB (0.37) | — | |
| SCHEMBL27794172 | 0.75 | KCNA5 (0.31) | MEN1ALDH1A1HTTKMT2AKCNA5 | |
| SCHEMBL20942728 | 0.75 | NLRP3 (0.32) | — | |
| SCHEMBL4242154 | 0.75 | LMNA (0.36) | ALDH1A1 | |
| SCHEMBL20034868 | 0.75 | CA2 (0.30) | — | |
| SCHEMBL25932730 | 0.75 | PTGS1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926321-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2018-03-27 | — | — | US | disclosed |
| US-8067415-B2 | Compounds useful as antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067457-B2 | Compounds useful as antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100016289-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20090197884-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090163497-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016289-A1 | Compounds Useful as Antagonists of CCR2 | CCR2, CCR1, CXCR3 | MEN1 3116/4885ALDH1A1 1338/4885HTT 2985/4885 |
| US-20090197884-A1 | Compounds Useful as Antagonists of CCR2 | CCR2, CCR1, CXCR3 | MEN1 3227/4885ALDH1A1 1292/4885HTT 3072/4885 |
| US-20090163497-A1 | Compounds Useful as Antagonists of CCR2 | CCR2, CCR1, CXCR3 | MEN1 3393/4885ALDH1A1 1385/4885HTT 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.